Healixa Inc. announces that Christopher Galliano will join its Board of Directors as a non-executive independent Director effective January 11, 2022, demonstrating the company's focus on corporate governance, growth and national list requirements. Mr. Galliano currently serves as Chief Technology Officer and Co-Founder of Skymount Medical, where he co-authored over 6 patents in artificial intelligence based drug discovery and leads the day to day research to construct an oral therapeutic for COVID-19 and 12 other active inventions/pharmaceutical developments.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.119 USD | +17.82% | +20.81% | -57.50% |
1st Jan change | Capi. | |
---|---|---|
-57.50% | 75.4M | |
+5.67% | 2,990B | |
+4.62% | 83.1B | |
+2.43% | 76.88B | |
-16.29% | 52.88B | |
+30.55% | 50.84B | |
-26.81% | 46.09B | |
+16.52% | 41.3B | |
+55.78% | 37.06B | |
-10.80% | 24.61B |
- Stock Market
- Equities
- EMOR Stock
- News Healixa Inc.
- Healixa, Inc. Appoints Christopher Galliano as Independent Director to its Board